Abstract
Hyperpolarization- and Cyclic Nucleotide-gated (HCN) channels are a family of six transmembrane domain, single pore-loop, hyperpolarization activated, non-selective cation channels. The HCN family consists of four members (HCN1-4). HCN channels represent the molecular correlates of Ih (also known as ‘funny’ If and ‘queer’ Iq), a hyperpolarization- activated current best known for its role in controlling heart rate and in the regulation of neuronal resting membrane potential and excitability. A significant body of molecular and pharmacological evidence is now emerging to support a role for these channels in the function of sensory neurons and pain sensation, particularly pain associated with nerve or tissue injury. As such, HCN channels may represent valid targets for novel analgesic agents. This evidence will be reviewed in this article. We will then summarize our efforts to develop and validate methods for screening for novel HCN channel blockers.
Combinatorial Chemistry & High Throughput Screening
Title: HCN Channels as Targets for Drug Discovery
Volume: 12 Issue: 1
Author(s): Alan D. Wickenden, Sandra R. Chaplan, Adrienne E. Dubin, Hong-Qing Guo, Nyan-Tsz Wu and Michael P. Maher
Affiliation:
Abstract: Hyperpolarization- and Cyclic Nucleotide-gated (HCN) channels are a family of six transmembrane domain, single pore-loop, hyperpolarization activated, non-selective cation channels. The HCN family consists of four members (HCN1-4). HCN channels represent the molecular correlates of Ih (also known as ‘funny’ If and ‘queer’ Iq), a hyperpolarization- activated current best known for its role in controlling heart rate and in the regulation of neuronal resting membrane potential and excitability. A significant body of molecular and pharmacological evidence is now emerging to support a role for these channels in the function of sensory neurons and pain sensation, particularly pain associated with nerve or tissue injury. As such, HCN channels may represent valid targets for novel analgesic agents. This evidence will be reviewed in this article. We will then summarize our efforts to develop and validate methods for screening for novel HCN channel blockers.
Export Options
About this article
Cite this article as:
Wickenden D. Alan, Chaplan R. Sandra, Dubin E. Adrienne, Guo Hong-Qing, Wu Nyan-Tsz and Maher P. Michael, HCN Channels as Targets for Drug Discovery, Combinatorial Chemistry & High Throughput Screening 2009; 12 (1) . https://dx.doi.org/10.2174/138620709787048028
DOI https://dx.doi.org/10.2174/138620709787048028 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis
Current Neurovascular Research The Trigeminal System in Birds and Nociception
Central Nervous System Agents in Medicinal Chemistry L-Acetylcarnitine: A Proposed Therapeutic Agent for Painful Peripheral Neuropathies
Current Neuropharmacology Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Ewing’s Sarcoma Cancer Stem Cell Targeted Therapy
Current Stem Cell Research & Therapy Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo
Current Drug Targets Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption
Recent Patents on Anti-Cancer Drug Discovery Editorial (Advances and Controversies in Stem Cell Therapies and Tissue Engineering Strategies Applicable to Trauma and Orthopaedic Surgery)
Current Stem Cell Research & Therapy Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design Current Trend and Pro-survival Approaches for Augmenting Stem Cell Viability
Current Pharmaceutical Biotechnology Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research Inhibition of the Function of TRPV1-Expressing Nociceptive Sensory Neurons by Somatostatin 4 Receptor Agonism: echanism and Therapeutical Implications
Current Topics in Medicinal Chemistry Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Current Medicinal Chemistry